Using 3'-azido-2',3'-dideoxythymidine (AZT) to prevent perinatal human immunodeficiency virus transmission and risk of transplacental carcinogenesis.
Reggy
A A
AA
Rogers
M F
MF
Simonds
R J
RJ
D000818:Animals; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002273:Carcinogens / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D051379:Mice; D009316:National Institutes of Health (U.S.); D010920:Placenta; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D012306:Risk; D014481:United States; D015215:Zidovudine / Q000008:administration & dosage / Q000009:adverse effects*
D019380:Anti-HIV Agents; D002273:Carcinogens; D015215:Zidovudine